Pre-revenue And Widening LossesThe company remains pre-revenue with materially widening net losses, indicating operating spend outpacing commercialization progress. Over multi-quarter horizons, continued lack of sales undermines sustainable margins and forces reliance on external capital, increasing execution risk.
Weak Cash Generation And Rising BurnConsistently negative operating and free cash flow with accelerating annual cash burn creates persistent funding needs. Even with no debt, ongoing outflows heighten dilution or financing risk and constrain the ability to fund expensive irradiation tests and regulatory qualification without external capital.
Commercialization Depends On Regulatory And Partner ExecutionLong-term commercial success hinges on multi-year testing, regulatory approvals and third-party manufacturing partnerships. Delays or failures in any of these durable, external-dependent steps could push revenue realization out years and increase cumulative R&D spend.